Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of dutasteride in reducing
drinking and heavy drinking in men and women with alcohol use disorder. The investigators
hypothesize that dutasteride 1 mg per day will be well tolerated in this patient population
and that, compared to placebo treatment, dutasteride will result in a greater reduction in
drinks per week and in the frequency of heavy drinking days.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
UConn Health
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)